An invention relates to pirfenidone application for human treatment, whereas the treatment includes avoiding or stopping accompanying application of pirfenidone with powerful inducer – cytochrome P450 1A2 (CYP1A2) or together introduction thereto avoid pirfenidone exposure reduction.